Europe’s Life Sciences Strategy. A New Era of Innovation?
The new European Life Sciences Strategy aims to accelerate pharmaceutical innovation through investment, regulatory reform, biotechnology, and AI capabilities.
Articles, expert interviews, and insights from life sciences leaders
How Should Pharma Companies Audit AI Vendors?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Read interview: How AI Is Opening New Opportunities in Fertility Care for Pharma
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
One Global CMC Dossier? Digital Regulatory Submissions
Discover how digital CMC regulatory submissions, cloud collaboration, and AI accelerate the modernisation of manufacturing approvals and global pharma operations.
Deep Learning in Clinical Trials for 2026 and Beyond
Deep learning is changing how clinical trials are designed, run, and analysed in 2026. Examine the tools, outcomes, and strategic risks shaping adoption.
GLP-1 Drug Discovery Success Transformed Pharmaceutical R&D
From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.
Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
FDA PreCheck Pilot Program to Build Manufacturing Readiness
The FDA PreCheck Pilot Program aims to strengthen U.S. domestic drug manufacturing through regulatory engagement, manufacturing readiness, and advanced production.
AI and Neuroscience. Why Big Pharma Is Betting on the Brain
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
FDA Master Protocol Guidance for Smarter Clinical Trials
Explore the FDA's Master Protocol guidance and how basket, umbrella, and platform trials can improve clinical trial efficiency, especially in oncology and biologics.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?
Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
FDA Registration for Drug Manufacturing Enters a New Era
The FDA's proposed drug manufacturing modernisation rule could accelerate distributed manufacturing, digital quality systems, and pharma supply chain resilience.
